Tag - AVXL


Dawson James starts Anavex at buy: PT $16

Dawson James initiated coverage of Anavex Life Sciences (NASDAQ:AVXL) with a “buy” rating and $16 price target. The stock closed $2.54 on July 23. Anavex is pioneering a new treatment in CNS diseases like...

Anavex readies trial of AZ combo drug

Anavex Life Sciences (OTCQB:AVXL) plans to begin a Phase 1b/2a clinical trial in the first quarter of 2014 of a novel combination drug candidate for the treatment of Alzheimer’s disease (AD). “In preclinical studies, we...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.